(European Society for Medical Oncology) Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.
Targeting specific genomic mutation in breast cancer improves outcomes, first study shows
Please login to join discussion
POPULAR NEWS
-
Saying Goodbye to PGY-6: Pediatric Fellowship Realities
-
Multi-Hospital Study Reveals Long Covid Burden Is Twice as High as Current Estimates
-
Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks
-
New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer